Navigation Links
Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
Date:1/31/2008

SEATTLE, Jan. 31 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of Daniel H. Petree and George R. Painter, Ph.D. to the Company's board of directors.

Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life science companies. Prior to forming P2 Partners, Mr. Petree held various executive management positions in the life sciences industry, including President and Chief Operating Officer of Axys Pharmaceuticals and Vice President of Business Development at TSI Corporation. He also served as Vice President in the Health Care Group at the investment bank Montgomery Securities. Mr. Petree currently serves as Director for Cypress BioSciences.

Dr. Painter is president and chief executive officer of Chimerix, a biotechnology company developing orally available antiviral therapeutics. Prior to that, he served as Executive Vice President, Research and Development, at Triangle Pharmaceuticals where he was a member of the founding management team. Dr. Painter has also held positions at Burroughs Wellcome Co., and Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-five patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit http://www.koronispharma.com.

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

julie@rathbuncomm.com

Tel : (206) 769-9219


'/>"/>
SOURCE Koronis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Access Pharmaceuticals Announces $2.7 Million New Equity
4. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
5. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
6. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
7. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, ... essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's ... is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, joins ... one of just six company finalists in the Health & Medicine category. Over ... nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/16/2016)... CLARA, Calif. , Nov. 16, 2016 ... enhancing user experience and security for consumer electronics, ... for the financial and retail industry, today announced ... secure and convenient way to authenticate users of ... uses Sensory,s TrulySecure™ software which requires ...
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
Breaking Biology News(10 mins):